America's biopharmaceutical research companies are developing 394 medicines and vaccines to combat infectious diseases. These include 226 medicines for viral infections like hepatitis, HPV, and herpes; 124 for bacterial infections such as pneumonia and tuberculosis; and medicines for fungal and parasitic infections. Many of these potential treatments target diseases where resistance to current treatments is growing, such as multi-drug resistant bacterial infections. The document outlines some examples of promising new treatments and vaccines in development for diseases like hepatitis C, HIV, malaria, and drug-resistant bacterial infections.